Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.08
PTX's Cash-to-Debt is ranked lower than
91% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. PTX: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
PTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.65 Max: No Debt
Current: 0.08
Equity-to-Asset -0.55
PTX's Equity-to-Asset is ranked lower than
99% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. PTX: -0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
PTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.55  Med: 0.43 Max: 0.99
Current: -0.55
-0.55
0.99
Piotroski F-Score: 1
Altman Z-Score: -3.25
Beneish M-Score: -5.99
WACC vs ROIC
12.54%
-64.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -98.90
PTX's Operating Margin % is ranked lower than
86% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. PTX: -98.90 )
Ranked among companies with meaningful Operating Margin % only.
PTX' s Operating Margin % Range Over the Past 10 Years
Min: -99.63  Med: -13.79 Max: 33
Current: -98.9
-99.63
33
Net Margin % -125.33
PTX's Net Margin % is ranked lower than
87% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. PTX: -125.33 )
Ranked among companies with meaningful Net Margin % only.
PTX' s Net Margin % Range Over the Past 10 Years
Min: -125.33  Med: -28.98 Max: 33.08
Current: -125.33
-125.33
33.08
ROA % -48.18
PTX's ROA % is ranked lower than
87% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. PTX: -48.18 )
Ranked among companies with meaningful ROA % only.
PTX' s ROA % Range Over the Past 10 Years
Min: -48.18  Med: -2.32 Max: 68.03
Current: -48.18
-48.18
68.03
ROC (Joel Greenblatt) % -9548.64
PTX's ROC (Joel Greenblatt) % is ranked lower than
96% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. PTX: -9548.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9548.64  Med: -9.14 Max: 1558.21
Current: -9548.64
-9548.64
1558.21
3-Year Revenue Growth Rate -8.20
PTX's 3-Year Revenue Growth Rate is ranked lower than
84% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. PTX: -8.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.25 Max: 105.4
Current: -8.2
0
105.4
3-Year EBITDA Growth Rate -14.50
PTX's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. PTX: -14.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -42 Max: 131.5
Current: -14.5
0
131.5
3-Year EPS without NRI Growth Rate 45.70
PTX's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PTX: 45.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -63 Max: 281.7
Current: 45.7
0
281.7
GuruFocus has detected 5 Warning Signs with Pernix Therapeutics Holdings Inc $PTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PTX Guru Trades in Q2 2016

Paul Tudor Jones 215,800 sh (New)
Jim Simons 2,214,396 sh (+1578.37%)
Steven Cohen Sold Out
» More
Q3 2016

PTX Guru Trades in Q3 2016

Jim Simons 4,843,189 sh (+118.71%)
Paul Tudor Jones Sold Out
» More
Q4 2016

PTX Guru Trades in Q4 2016

Jim Simons 692,950 sh (+43.08%)
» More
Q1 2017

PTX Guru Trades in Q1 2017

Jim Simons 740,650 sh (+6.88%)
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:BPTH, OTCPK:MGWFF, NAS:OREX, NAS:JNP, NAS:SCYX, NAS:EVOK, OTCPK:IMLFF, OTCPK:SENZ, OTCPK:NRIFF, NAS:FCSC, OTCPK:STNY, OTCPK:MRPHF, NAS:MEIP, OTCPK:ITHUF, NAS:SNOA, NAS:EPIX, OTCPK:CVSI, OTCPK:KAYS, OTCPK:GLDFF, NAS:LPCN » details
Traded in other countries:GTAQ.Germany,
Headquarter Location:USA
Pernix Therapeutics Holdings Inc is a specialty pharmaceutical company engaged in identifying, developing and commercializing differentiated products that address unmet medical needs.

Pernix Therapeutics Holdings Inc is a specialty pharmaceutical company engaged in identifying, developing and commercializing differentiated products that address unmet medical needs. Its portfolio of approved products that address medical needs in several therapeutic areas, including Migraine, Treximet fixed dose combination product indicated for the treatment of acute migraine; Pain: Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate; and Insomnia, Silenor, the only non-narcotic, non-scheduled and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance.

Top Ranked Articles about Pernix Therapeutics Holdings Inc

Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength
Pernix: An Investor's Rationale to Staying Long The stock has fallen a bit, but there's a good reason investors are staying long
I am letting you know from the beginning, I am long Pernix Therapeutics Holdings Inc. (NASDAQ:PTX). While I may have gotten to the point where I play hide-and-seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I am not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutiae and get to the nitty gritty of the issue at hand. As such, despite Pernix's current issues, I still see significant upside value. Read more...
Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28

MORRISTOWN, N.J., March 15, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that the Company will report financial results for the fourth quarter and year ended December 31, 2016, after the market close on Tuesday, March 28, 2017.  John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
Date: Tuesday, March 28   Time: 4:30 PM ET  Toll free (U.S.): 888-576-4382 International:  719-457-2735 Conference ID: 4228557 Webcast: http://public.viavid.com/index.php?id=123412 About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its integrated Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com
CONTACT
Investor Relations
Matthew P. Duffy, 212-915-0685
LifeSci Advisors, LLC
[email protected]

Read more...
Major Second Quarter Purchases for Cohen Include Tesaro, Pernix Purchases 5% of company or greater available, portfolio update yet to be released
The official second quarter portfolio update for Steven Cohen (Trades, Portfolio), owner of Point72 Asset Management, has not been released as of July 20. Buys made that were greater than 5% of the company are available, however. The GuruFocus real time updates indicate Cohen purchased shares in Cynosure Inc. (CYNO), Pernix Therapeutics (NASDAQ:PTX), Tesaro Inc. (NASDAQ:TSRO) and Tetra Technologies (TTI) over the course of the second quarter. These purchases were made April 25, April 28, May 9, and June 27, respectively.  Read more...
Platinex Inc. - Completion of Interim Closing of Private Placement & Extension

TORONTO, ONTARIO--(Marketwired - Jun 28, 2016) - Platinex Inc. (TSX VENTURE:PTX) (the "Company") is pleased to announce that it has completed an interim closing of its previously announced non-brokered private placement (the "Private Placement"), issuing a total of 8,000,000 units ("Units") for aggregate gross proceeds of $200,000 (the "Interim Closing"). Each Unit consists of one common share ("Common Share") of the Company and one warrant ("Warrant") of the Company, bearing the terms described in the initial press release announcing the Private Placement ("Initial Press Release"). The Company intends to use the net proceeds of the Interim Closing in accordance with use of proceeds described in the Initial Press Release. A qualifying report on the Shining Tree gold property will be produced including a valuation of the Herrick gold deposit. All securities issued in connection with this Private Placement will be subject to a four month hold period from the date of issuance in accordance with applicable securities laws. The closing of the Private Placement, including the Interim Closing, is subject to receipt of approvals of the TSX Venture Exchange ("TSX-V") and other applicable securities regulatory authorities. Extension of Final Closing Date & Issuance of Broker Units The TSXV has granted the Company an extension until July 27, 2016 to raise an additional $175,000 under the Private Placement. The Company will be seeking subscriptions under various prospectus exemptions including Existing Security Holder prospectus exemptions. For further details regarding the Private Placement and how to participate, see the Initial Press Release. In addition to the 7% finder's fee to registered finders announced in the Initial Press Release, the TSX-V has also approved the Company's issuance of broker units for 7% of amounts raised by registered brokers participating in the Private Placement, exercisable into Units within 24 months of the relevant closing ("Broker Units"). Details of Initial Closing In connection with the Initial Closing, the Company paid $6,300 of finder's fees and issued 252,000 Broker Units. Insiders of the Company subscribed for 1,000,000 Units in connection with the Interim Closing and such subscriptions are considered related party transaction within the meaning of Multilateral Instrument 61-101 ("MI 61-101"). The Company is relying on an exemption from the valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of any Insider Participation; at the time the transaction was agreed to, neither the fair market value of the subject matter of, nor the fair market value consideration for the transaction, as it related to insiders, exceeded 25% of the Company's market capitalization. About Platinex Inc. Platinex has revealed strong evidence of a major gold bearing zone on its Shining Tree property as evidenced by a provincially significant, extraordinarily high gold content of soil samples (glacial till) along a nine km long corridor. Platinex is expanding exploration on the Herrick gold deposit with 62 holes drilled to date with an average grade of 2.10 g/tonne gold. Shares of Platinex are listed for trading on the TSX Venture Exchange under the symbol "PTX". The information presented in this news release has been reviewed and approved by James R. Trusler, Geological Engineer, the Chief Executive Officer of the Company and the Qualified Person for exploration at the Shining Tree property, as defined by National Instrument 43-101 "Standards of Disclosure for Mineral Projects". To receive Company press releases, please email [email protected] and mention "Platinex press release" on the subject line. FORWARD-LOOKING STATEMENTS: Except for statements of historical fact, all statements in this news release - including, without limitation, statements regarding future plans and objectives, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate; actual results and future events could differ materially from those anticipated in such statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Platinex Inc.
James R. Trusler
President and CEO
(416) 565-5616
[email protected]
www.platinex.com




Read more...
Steven Cohen Adds to Stake in Pernix Therapeutics Company has drastically increased gross profits and net revenues over the previous 6 years
Steven Cohen (Trades, Portfolio) raised his stake in Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) by nearly 49% with the purchase of 1,224,544 shares on April 28. Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.28
PTX's PS Ratio is ranked higher than
98% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. PTX: 0.28 )
Ranked among companies with meaningful PS Ratio only.
PTX' s PS Ratio Range Over the Past 10 Years
Min: 0.07  Med: 1.54 Max: 8.85
Current: 0.28
0.07
8.85
EV-to-EBIT -2.31
PTX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. PTX: -2.31 )
Ranked among companies with meaningful EV-to-EBIT only.
PTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -163.1  Med: -2.8 Max: 280.5
Current: -2.31
-163.1
280.5
EV-to-EBITDA -32.90
PTX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. PTX: -32.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -354.4  Med: 7.9 Max: 280.5
Current: -32.9
-354.4
280.5
Current Ratio 0.88
PTX's Current Ratio is ranked lower than
89% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. PTX: 0.88 )
Ranked among companies with meaningful Current Ratio only.
PTX' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.61 Max: 64.5
Current: 0.88
0.84
64.5
Quick Ratio 0.79
PTX's Quick Ratio is ranked lower than
81% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. PTX: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
PTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.45 Max: 64.5
Current: 0.79
0.62
64.5
Days Inventory 78.02
PTX's Days Inventory is ranked higher than
70% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. PTX: 78.02 )
Ranked among companies with meaningful Days Inventory only.
PTX' s Days Inventory Range Over the Past 10 Years
Min: 36.32  Med: 91.6 Max: 220.74
Current: 78.02
36.32
220.74
Days Sales Outstanding 81.92
PTX's Days Sales Outstanding is ranked lower than
79% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. PTX: 81.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.01  Med: 124.16 Max: 208.1
Current: 81.92
54.01
208.1
Days Payable 63.04
PTX's Days Payable is ranked lower than
58% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. PTX: 63.04 )
Ranked among companies with meaningful Days Payable only.
PTX' s Days Payable Range Over the Past 10 Years
Min: 28.65  Med: 56.72 Max: 150.75
Current: 63.04
28.65
150.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -39.10
PTX's 3-Year Average Share Buyback Ratio is ranked lower than
91% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. PTX: -39.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -109.5  Med: -1.75 Max: 1.7
Current: -39.1
-109.5
1.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.17
PTX's Price-to-Median-PS-Value is ranked higher than
98% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. PTX: 0.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.41 Max: 5.79
Current: 0.17
0
5.79
Earnings Yield (Greenblatt) % -43.12
PTX's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. PTX: -43.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -43.12  Med: 6.5 Max: 16.7
Current: -43.12
-43.12
16.7

More Statistics

Revenue (TTM) (Mil) $138.1
EPS (TTM) $ -20.73
Beta1.69
Short Percentage of Float19.13%
52-Week Range $1.83 - 10.40
Shares Outstanding (Mil)10.02

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 165 135
EPS ($) 0.10 -0.54
EPS without NRI ($) 0.10 -0.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15 May 08 2017 
Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Streng May 01 2017 
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 2 Mar 15 2017 
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Platinex Inc. - Completion of Interim Closing of Private Placement & Extension Jun 28 2016 
Steven Cohen Adds to Stake in Pernix Therapeutics Jun 07 2016 
Platinex Inc.-Proposed Private Placement May 12 2016 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 

More From Other Websites
Edited Transcript of PTX earnings conference call or presentation 15-May-17 8:30pm GMT May 21 2017
Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19,... May 19 2017
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 16, 2017 May 16 2017
Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update May 15 2017
Investor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call May 15 2017
Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15 May 08 2017
Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength May 01 2017
Rennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price... Apr 24 2017
Platinex Inc.-Proposed Private Placement Apr 18 2017
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 7, 2017 Apr 07 2017
Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5,... Apr 05 2017
Today's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics Mar 30 2017
Edited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT Mar 28 2017
Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results Mar 28 2017
Pernix: An Investor's Rationale to Staying Long Mar 23 2017
Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March... Mar 15 2017
Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and... Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)